153 related articles for article (PubMed ID: 8976818)
21. Activation of the nuclear transcription factor kappaB (NFkappaB) and differential gene expression in U87 glioma cells after exposure to the cytoprotector amifostine.
Kataoka Y; Murley JS; Khodarev NN; Weichselbaum RR; Grdina DJ
Int J Radiat Oncol Biol Phys; 2002 May; 53(1):180-9. PubMed ID: 12007958
[TBL] [Abstract][Full Text] [Related]
22. Amifostine (ETHYOL) protects rats from mucositis resulting from fractionated or hyperfractionated radiation exposure.
Cassatt DR; Fazenbaker CA; Bachy CM; Kifle G; McCarthy MP
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):901-7. PubMed ID: 15708273
[TBL] [Abstract][Full Text] [Related]
23. The effect of the radioprotector WR-2721 and WR-1065 on mitochondrial lipid peroxidation.
Tretter L; Rónai E; Szabados G; Hermann R; Andó A; Horváth I
Int J Radiat Biol; 1990 Mar; 57(3):467-78. PubMed ID: 1968940
[TBL] [Abstract][Full Text] [Related]
24. The efficacy of selenium, WR-2721, and their combination in the prevention of adriamycin-induced cardiotoxicity in rats.
Dobrić S; Dragojević-Simić V; Bokonjić D; Milovanović S; Marincić D; Jović P
J Environ Pathol Toxicol Oncol; 1998; 17(3-4):291-9. PubMed ID: 9726805
[TBL] [Abstract][Full Text] [Related]
25. Delayed radioprotection by NFkappaB-mediated induction of Sod2 (MnSOD) in SA-NH tumor cells after exposure to clinically used thiol-containing drugs.
Murley JS; Kataoka Y; Cao D; Li JJ; Oberley LW; Grdina DJ
Radiat Res; 2004 Nov; 162(5):536-46. PubMed ID: 15624308
[TBL] [Abstract][Full Text] [Related]
26. Subcutaneous administration of amifostine (ethyol) is equivalent to intravenous administration in a rat mucositis model.
Cassatt DR; Fazenbaker CA; Kifle G; Bachy CM
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):794-802. PubMed ID: 14529786
[TBL] [Abstract][Full Text] [Related]
27. Amifostine (Ethyol): pharmacokinetic and pharmacodynamic effects in vivo.
van der Vijgh WJ; Korst AE
Eur J Cancer; 1996; 32A Suppl 4():S26-30. PubMed ID: 8976819
[TBL] [Abstract][Full Text] [Related]
28. WR-2721, its derivatives and their radioprotective effects on mammalian cells in culture.
Mori T; Watanabe M; Horikawa M; Nikaido P; Kimura H; Aoyama T; Sugahara T
Int J Radiat Biol Relat Stud Phys Chem Med; 1983 Jul; 44(1):41-53. PubMed ID: 6305861
[TBL] [Abstract][Full Text] [Related]
29. Efficiency of amifostine as a protection against doxorubicin toxicity in rats during a 12-day treatment.
Nazeyrollas P; Frances C; Prevost A; Costa B; Lorenzato M; Kantelip JP; Elaerts J; Millart H
Anticancer Res; 2003; 23(1A):405-9. PubMed ID: 12680240
[TBL] [Abstract][Full Text] [Related]
30. Determination of the cytoprotective agent WR-2721 (Amifostine, Ethyol) and its metabolites in human blood using monobromobimane fluorescent labeling and high-performance liquid chromatography.
Souid AK; Newton GL; Dubowy RL; Fahey RC; Bernstein ML
Cancer Chemother Pharmacol; 1998; 42(5):400-6. PubMed ID: 9771955
[TBL] [Abstract][Full Text] [Related]
31. WR-1065, the active metabolite of amifostine, mitigates radiation-induced delayed genomic instability.
Dziegielewski J; Baulch JE; Goetz W; Coleman MC; Spitz DR; Murley JS; Grdina DJ; Morgan WF
Free Radic Biol Med; 2008 Dec; 45(12):1674-81. PubMed ID: 18845240
[TBL] [Abstract][Full Text] [Related]
32. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine.
Capizzi RL
Semin Oncol; 1999 Apr; 26(2 Suppl 7):3-21. PubMed ID: 10348255
[TBL] [Abstract][Full Text] [Related]
33. Radioprotection of cells in culture by WR-2721 and derivatives: form of the drug responsible for protection.
Smoluk GD; Fahey RC; Calabro-Jones PM; Aguilera JA; Ward JF
Cancer Res; 1988 Jul; 48(13):3641-7. PubMed ID: 2837320
[TBL] [Abstract][Full Text] [Related]
34. Interaction of cultured mammalian cells with WR-2721 and its thiol, WR-1065: implications for mechanisms of radioprotection.
Purdie JW; Inhaber ER; Schneider H; Labelle JL
Int J Radiat Biol Relat Stud Phys Chem Med; 1983 May; 43(5):517-27. PubMed ID: 6303973
[TBL] [Abstract][Full Text] [Related]
35. Effect of amifostine on the cytotoxicity of daunorubicin and daunoxome in tumor and normal cells.
Michelutti A; Stocchi R; Candoni A; Tiribelli M; Calistri E; Russo D; Fanin R; Damiani D
Cancer Chemother Pharmacol; 2006 Apr; 57(4):517-24. PubMed ID: 16001170
[TBL] [Abstract][Full Text] [Related]
36. Cytoprotection by WR-1065, the active form of amifostine, is independent of p53 status in human malignant glioma cell lines.
Kataoka Y; Murley JS; Patel R; Grdina DJ
Int J Radiat Biol; 2000 May; 76(5):633-9. PubMed ID: 10866285
[TBL] [Abstract][Full Text] [Related]
37. Thiol WR-1065 and disulphide WR-33278, two metabolites of the drug ethyol (WR-2721), protect DNA against fast neutron-induced strand breakage.
Savoye C; Swenberg C; Hugot S; Sy D; Sabattier R; Charlier M; Spotheim-Maurizot M
Int J Radiat Biol; 1997 Feb; 71(2):193-202. PubMed ID: 9120355
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of spontaneous metastases formation by amifostine.
Grdina DJ; Kataoka Y; Murley JS; Hunter N; Weichselbaum RR; Milas L
Int J Cancer; 2002 Jan; 97(2):135-41. PubMed ID: 11774255
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics of amifostine and its metabolites in patients.
Korst AE; Eeltink CM; Vermorken JB; van der Vijgh WJ
Eur J Cancer; 1997 Aug; 33(9):1425-9. PubMed ID: 9337685
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic profile of amifostine.
Shaw LM; Bonner H; Lieberman R
Semin Oncol; 1996 Aug; 23(4 Suppl 8):18-22. PubMed ID: 8783662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
